Given that CSF-1R inhibitors are under active study in clinical trials, including in breast cancer, positive CSF-1R staining in clinical breast cancer specimens and its association with immune cells could help identify which patients might best benefit from combination with immunotherapies. The gene discussed is CSF1R; the disease is breast cancer.